Atlas Trials

Other Solid Tumors

31 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Other Solid Tumors

RecordFirmDate
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor (NCT05332574)Genor Biopharma Co., Ltd.2022-05-17
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (NCT05121948)HiberCell, Inc.2022-02-23
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors (NCT05393427)Sichuan Baili Pharmaceutical Co., Ltd.2022-02-15
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) (NCT04834778)HiberCell, Inc.2021-06-08
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943)Celldex Therapeutics2020-08-04
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China (NCT04121286)Allist Pharmaceuticals, Inc.2020-07-14
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors (NCT04045496)Jacobio Pharmaceuticals Co., Ltd.2019-09-26
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (NCT03947385)IDEAYA Biosciences2019-06-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950)Celldex Therapeutics2017-12-01
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889)AbbVie2016-09-23
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (NCT02819843)Memorial Sloan Kettering Cancer Center2016-06-21
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. (NCT02711345)Novartis Pharmaceuticals2016-04-15
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (NCT02573259)Pfizer2016-02-10
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813)Novartis Pharmaceuticals2016-01-18
Phase I/II Study of PDR001 in Patients With Advanced Malignancies (NCT02404441)Novartis Pharmaceuticals2015-04-27
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) (NCT00106145)Merck Sharp & Dohme LLC2005-04-01
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors (NCT00064636)Millennium Pharmaceuticals, Inc.2002-12-01

Track Other Solid Tumors automatically

Every clearance here is in the API, with alerts when new ones post.